5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Human Microbiome Market is segmented by Application, Disease, Product (Probiotics, Prebiotics, Symbiotic, Other Diseases), and Geography
Fastest Growing Market:
The global human microbiome market is expected to show a CAGR of 22.60% during the forecast period. The key factors propelling the growth of this market are increasing incidence of lifestyle-related diseases and growing geriatric population.
The rising incidence of lifestyle-related diseases, globally, is a strong driver of the human microbiome market, as therapeutics may provide an alternative route to tackle significant healthcare challenges, such as obesity. The increasing occurrence of autoimmune disorders and antibiotic resistance are also important areas, which are in great need of fresh treatment approaches, and for which, microbiome therapies may have a significant impact over the next few years. With advancements in precision medicine, personalized nutrition is also playing a crucial role. Microbiome technologies strive for novel developments in the area. Cardiovascular diseases (CVD) continue to be the major cause of mortality, representing about 30% of all deaths, worldwide. Lifestyle-related diseases, like hypertension, diabetes mellitus, dyslipidaemia, and overweight/obesity, are the major risk factors for the development of CVD. With rapid economic development and increasing westernization of lifestyles in the past few decades, the prevalence of these diseases has reached alarming proportions in the recent years, which is expected to boost the growth of the human microbiome market.
The global human microbiome market comprises various therapeutic and diagnostic products that include human microbiota. The market also includes disease indication. The size of the market has been estimated based on the revenues generated from therapies and diagnostic techniques.
Report scope can be customized per your requirements. Click here.
The therapeutic applications segment is expected to have the largest market share during the forecast period and is likely to register a CAGR of 22.93%.
The microbiome-based products for therapeutics are still in the development phase. There are a number of organizations that are developing products across various disease areas in the human microbiome space. Companies have developed their own proprietary technology platforms and innovative approaches to microbiome-based treatment. The most common strategy deployed for a variety of products is the use of natural, live bacteria, either as a single agent or in a mixture form. Some companies are engineering bacteria and are programing them to take over certain physiologic functions to tackle rare disorders.
To understand key trends, Download Sample Report
North America currently dominates the market for human microbiome and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. It is also the largest market for microbiome-based products, globally. The growth of the market is majorly due to the high level of awareness about the beneficial aspects of microbiome-based products and initiatives, like the NIH human microbiome project, which have been responsible for generating a holistic understanding of concepts, like metagenomic and whole genome sequencing.
To understand geography trends, Download Sample Report.
The human microbiome market is less competitive currently and consists of several players that are coming up with products. Companies, like Yakult, DuPont, Series Therapeutics, Second Genome, and Synthetic Biologics, hold substantial shares in the market.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Lifestyle-related Diseases
4.2.2 Growing Geriatric Population
4.3 Market Restraints
4.3.1 Lack of Comprehensive Research
4.3.2 Stringent Government Regulations
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.2.3 Autoimmune Disorder
5.2.5 Gastrointestinal Disorders
5.2.6 Central Nervous System Disorders
5.2.7 Other Diseases
5.3.4 Other Products
5.4.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.4.4 Middle East & Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East & Africa
5.4.5 South America
188.8.131.52 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Enterome Bioscience
6.1.4 Seres Therapeutics
6.1.5 Vithera Pharmaceuticals
6.1.6 Second Genome Inc.
6.1.7 Synthetic Biologics Inc.
6.1.8 Vedanta Biosciences Inc.
6.1.9 Osel Inc.
6.1.10 Synlogic Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments